4.6 Article

Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure

期刊

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
卷 69, 期 7, 页码 1815-1825

出版社

WILEY
DOI: 10.1111/jgs.17108

关键词

sarcopenia; heart failure; aging; clinical outcomes; inpatient mortality

资金

  1. American College of Gastroenterology
  2. National Institutes of Health [P50 AA024333, RO1 AA021890, 3U01AA026976-03S1, 5U01DK062470-17S2, K12 HL141952, R21 AR 071046, RO1 GM119174, RO1 DK113196, UO1 AA 026976, R56HL141744, UO1 DK061732]

向作者/读者索取更多资源

The study revealed that in hospitalized patients with heart failure, older age was associated with a higher prevalence of muscle loss phenotype, leading to worse clinical outcomes for the patients.
Objectives Skeletal muscle loss or sarcopenia is a frequent complication in heart failure (HF) and contributes to adverse clinical outcomes. We evaluated if age (primary) and chronic disease (secondary) related sarcopenia, that we refer to as compound sarcopenia, impacts clinical outcomes in hospitalized patients with HF. Design Cross-sectional study using hospitalized patient data. Setting Data from the Agency for Healthcare Research and Quality through the Healthcare Cost and Utilization Project (HCUP). Participants Hospitalized adult patients with a primary or secondary diagnosis of HF (n = 64,476) and a concurrent random 2% sample of general medical population (GMP; n = 322,217) stratified by age (<50 years of age [y], 51-65y, >65y) from the Nationwide Inpatient Sample (NIS) database (years 2010-2014). Measurements In-hospital mortality, length of stay (LoS), cost of hospitalization per admission (CoH), comorbidities and discharge disposition, with and without muscle loss phenotype, were analyzed. Muscle loss phenotype was defined using a comprehensive code set from international classification of diseases-9 (ICD-9). Results Muscle loss phenotype was observed in 8673 (13.5%) patients with HF compared to 5213 (1.6%) GMP across all age strata. In patients with HF, muscle loss phenotype was associated with higher mortality, LoS, and CoH. Patients with HF (>65y) and muscle loss phenotype had higher mortality (adjusted OR: 1.81; 95% CI 1.56-2.10), CoH (adjusted OR 1.48; 95% CI 1.44-1.1.52), and LoS (adjusted OR 1.40; 95% CI 1.37-1.43) compared to >65y GMP with muscle loss phenotype. Conclusion Muscle loss phenotype is more commonly associated with increasing age in hospitalized patients with HF. Clinical outcomes were significantly worse in patients with HF aged >65y compared to younger patients with HF and all age strata in GMP with and without a muscle loss phenotype.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据